“R.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
VANCOUVER, British Columbia, 25 August 2020 (GLOBE NEWSWIRE) – EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2), (the “Company” or “EXM”), a life sciences start-up that specializes in the production of cannabinoid formulations, is pleased to announce the advancement of its studies and progression operations at its Lisbon plant in Lisbon, Portugal. The Company will provide the following updates on ongoing studies and progression operations:
Earlier this year, EXM implemented a P2020 study fellowship under the so-called SkanABility Project for a proof-of-concept examination of the biological activity of cannabinoids and terpenes in cooler applications. The work aims to demonstrate the advertising capacity of hash compounds in cosmetics and aromatherapy products, as well as to expand sustainable and functional packaging based on biodegradable hash fabrics (fibers and waxes), which will increase the shelf life of products and maintain them. . formulations and properties. SkanABility will expand formulas for other types of cosmetics and aromatherapy (facial cleansers for acne, antiproliferative / regenerative, anti-inflammatory / hypoallergenic, essential oils for aromatherapy, etc.) that EXM plans to sell to advertising and pharmaceutical corporations. Royalty. founded business model.
Recently, EXM submitted a request to the Portuguese government through the COVID-19 I-D initiative and began investigating the virucidal efficacy of hashish and terpene molecules in combating SARS-CoV-2, the guilty virus of COVID-19. Early indications recommend that molecules can inhibit the killing of the virus on surfaces by attacking its cell structure. If proven to be effective, these molecules can be key parts of the advertising responses used to combat the spread of the virus.
EXM believes that these molecules will be effective in eliminating the virus and will be applicable in the following key areas:
Disinfection of surfaces and properties
Hand and frame disinfection
Additional coating in social and surgical masks.
Currently, disinfectants have a maximum alcohol content of 60% or more, which can damage tissues, aggravate the skin and cause illness if accidentally swallowed. In addition, hydrogen peroxide responses are flammable and corrosive to the skin, eyes and mucous membranes at maximum concentrations (up to 10%) and can cause irritation. Herbal-containing hash disinfectants and wild plant ingredients have many potential benefits as they are softer for skin and surfaces and more environmentally sustainable.
COVID-19 is a turning point in our history and has replaced the way we look at hygiene and cleaning criteria. This has created incredibly superior demand for cleaning products across all sectors, and consumers will be in favor of herbal and effective alternatives, such as those explored through EXM, which are less frustrating to the skin, less harmful to fabrics and surfaces, and more. environmentally sustainable.
ON BEHALF OF THE BOARD OF DIRECTORS OF EXMCEUTICALS INC.
Jonathan Summers, President and CEO
Press Requests: Email: [email protected]
FOR MORE UPDATES ON THE COMPANY
Follow us on Twitter: https://twitter.com/EXMceuticals Follow us on LinkedIn: https://www.linkedin.com/company/exmceuticalsinc/
ABOUT EXMCEUTICS
EXM’s core activities focus on the strategic combination of herbal bioactive ingredients extracted from the hash plant with the wishes of the nutraceutical, cosmeceutical and curative industries. EXMceuticals Portugal, received from INFARMED in November 2019, has an exclusive authorization for the importation of hashish and studies and progression in its specially provided laboratory in Lisbon, Portugal. The ExM team is composed of highly qualified clinical and control professionals covering all required spaces throughout the hashish industry: biological and analytical chemistry, biology, biochemistry, genetics, compliance, intellectual property, associations and legal and regulatory issues.
EXM is in the final stages of developing detailed plans for an industrial-scale pharmaceutical criteria facility in Portugal to complement its studies and progression laboratory and pilot refinery. An existing asset has been secured in Setubal, south of Lisbon, which requires adaptation to the EU-GMP/API criteria. Once completed, the facility will have extraction, purification and refining capabilities, as well as a query and response laboratory. Once built, we believe that the Setubal facility will be the largest extraction, purification and refining facility for cannabinoids and terpenes in the European Union.
The refinery will process biomass, hash extracts and distillates from Portugal, as well as foreign resources where THE regulatory import needs of INFARMED have been met. EXM has several memorandums of understanding that will ensure that the refinery can operate at its original capacity from day one and then expand further. This refinery, once authorized, will distribute hash medical ingredients on a B2B basis to produce APIs and hash-based compounds in a reliable, uniform and standardized procedure. EXM aims and maintains the highest certification criteria to meet the wishes of the pharmaceutical, nutraceutical and cosmetic industries around the world.
CSE: EXM FSE: A2PAW2
Neither the ESC nor the ESF nor defusing the contents of this press release. Neither the CSE nor the ESF assumes the duty of the relevance or accuracy of this release.
Certain data contained in this document would possibly constitute “prospective data” under Canadian securities law. As a general rule, prospective data would possibly be known through the use of forward-looking terms such as “will,” “anticipate,” “propose,” “intend, or diversify” words and words or statements that I’m sure actions, occasions, or effects will “occur.” Forward-looking statements relating to the Company’s business activities, the extraction of hash ingredients and the export of extracts, verification effects on our established amenities for the European market, long-term legislation and regulations governing the sale of our products in Europe and elsewhere, and the possibility of generating sales and eligible financing are subject to hazards Fixed and other known and unknown points that would possibly cause the actual effects, point of activity, functionality or achievements of EXM differ materially from those expressed or implied by such forward-looking statements or forward-looking data. It cannot be guaranteed that such statements prove to be accurate, since actual effects and long-term occasions may differ materially from those expected in those statements. Readers therefore deserve not to place undue reliance on forward-looking statements and forward-looking data. EXM will not update any forward-looking statements or forward-looking data that are incorporated by reference to such statements, as required by applicable securities law.